This article is available to subscribers. Subscribe now. Already have an account? Sign in

Original ArticleFree PreviewArchive

Effects of Digoxin in Infants with a Congested Circulatory State Due to a Ventricular Septal Defect

List of authors.
  • William Berman, Jr., M.D.,
  • Steven M. Yabek, M.D.,
  • Terrence Dillon, M.D.,
  • Colleen Niland, R.N.,
  • Sue Corlew, R.D.M.S.,
  • and Deborah Christensen, B.S.

Abstract

Digoxin alone was used to treat a congested circulatory state in 21 infants (mean age, 2.7 months; mean weight, 3.8 kg) with a ventricular septal defect. The dose was adjusted on the basis of pharmacokinetics to achieve a mean steady-state concentration of 1.6±0.3 ng of digoxin per milliliter of serum. The mean red-cell level of sodium–potassium ATPase fell from 23.1±7.0 to 12.6±5.2 nmol per milligram per minute with treatment. Only 6 of the 21 patients had an inotropic response, as reflected by echocardiographic measurements, but the drug was of clinical benefit to 12 infants (including these 6). These results show that not all infants with a congested circulatory state due to a ventricular septal defect benefit from digoxin therapy. Furthermore, in some subjects clinical improvement occurs in the absence of a measurable inotropic response. (N Engl J Med. 1983; 308:363–6.)

Funding and Disclosures

Supported in part by a grant (HL 23980) from the National Institutes of Health.

Author Affiliations

From the Cardiology Section, Department of Pediatrics, University of New Mexico Hospital, Albuquerque, NM 87131, where reprint requests should be addressed to Dr. Berman.

Print Subscriber? Activate your online access.